PeptiDex
Peptide Research Index
Research-backed
Peptide Research Index
⚠️ Educational only · Not medical advice · Consult a doctor · Most peptides are research-only / not FDA-approved for human use
⚠️ Educational only · Not medical advice · Consult a doctor · Most peptides are research-only / not FDA-approved for human use
Also: Mounjaro, Zepbound
🔥Dual Agonist (GLP-1/GIP)Dual receptor agonism at GLP-1 and GIP receptors for synergistic appetite suppression, improved insulin sensitivity, and enhanced metabolic function.
Jastreboff et al. (NEJM): Phase 3 SURMOUNT-1 trial tirzepatide 15mg achieved 22.5% body weight reduction vs 2.4% placebo at 72 weeks in 2,539 adults with obesity.
very strongAronne et al.: 176-week data showing sustained weight loss maintenance with continued tirzepatide treatment 15mg dose maintained -19.7% weight reduction.
very strongMeta-analysis of multiple RCTs confirming tirzepatide significantly reduces BMI, waist circumference, body weight, and HbA1c across diverse patient populations.
very strongFrias et al. (NEJM): SURPASS-1 trial showing tirzepatide reduces HbA1c by up to 2.07% and body weight by 9.5 kg in type 2 diabetes. Superior to semaglutide in head-to-head trials.
very strongFDA-approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). GI side effects common but manageable. Well-studied long-term safety.
⚠️ For educational purposes only. Not medical advice. Consult a healthcare professional before using any peptide.
Start 2.5mg weekly, escalate every 4 weeks: 5mg → 7.5mg → 10mg → 12.5mg → 15mg. Prescription required.
Last updated: 2026-01 · Laws change frequently. Verify current status in your jurisdiction.
Week 1
GI adjustment period; appetite suppression begins
Weeks 2-4
5-8% weight reduction at therapeutic dose
Month 2-3
15-20% body weight reduction at 15mg
Long-term
22.5% weight loss at 72 weeks (SURMOUNT-1); superior to semaglutide in head-to-head
| Side Effect | Incidence | Severity |
|---|---|---|
Nausea From SURMOUNT-1 Phase 3 trial | ~32% of users | moderate |
Diarrhea | ~23% of users | mild |
Vomiting | ~20% of users | moderate |
Constipation | ~18% of users | mild |
Hypoglycemia Risk higher when combined with insulin | ~5% of users | moderate |
Incidence rates sourced from published clinical trial data where available; otherwise based on community research observations.
Maximize fat loss while preserving or building lean muscle the gold standard for total body transformation
Improve metabolic health, insulin sensitivity, and cellular energy production
Weekly Peptide Research
New studies · vendor alerts · protocol tips
No spam. Unsubscribe anytime. Research use only.